Exicure to Present at Upcoming Scientific Conferences
October 07 2021 - 7:00AM
Business Wire
Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and
immunotherapeutic drugs utilizing spherical nucleic acid (SNA™)
technology, today announced presentations in the following
scientific conferences during the month of October:
17th International Congress on Neuronal Ceroid Lipofuscinosis
(NCLs) Title: "Development of Spherical Nucleic Acids Targeting
CLN3 for the Treatment of Batten Disease" Presented by: Grant
Corbett, Group Lead, Neuroscience Date: Friday, October 8, 2021
Time: 4:50 - 5:05 PM CDT
International OligonucIeotides and Peptides Conference (IOPC)
2021 Title: “Spherical Nucleic Acids Facilitate Efficient Local
Delivery Across Therapeutic Areas” Presented by: Matthias Schroff,
COO Date: Monday, October 18, 2021 Time: 8:55 - 9:25 AM CDT
About Exicure, Inc.
Exicure, Inc. is a clinical-stage biotechnology company
developing therapeutics for neurology, immuno-oncology,
inflammatory diseases and other genetic disorders based on its
proprietary Spherical Nucleic Acid, or SNA technology. Exicure
believes that its proprietary SNA architecture has distinct
chemical and biological properties that may provide advantages over
other nucleic acid therapeutics and may have therapeutic potential
to target diseases not typically addressed with other nucleic acid
therapeutics. Exicure is in preclinical development of XCUR-FXN, a
lipid-nanoparticle SNA–based therapeutic candidate, for the
intrathecal treatment of Friedreich’s ataxia (FA). Exicure’s
therapeutic candidate cavrotolimod (AST-008) is in a Phase 1b/2
clinical trial in patients with advanced solid tumors. Exicure is
based in Chicago, IL and in Cambridge, MA. www.exicuretx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211007005139/en/
Karen Sharma MacDougall 781-235-3060 ksharma@macbiocom.com
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exicure (NASDAQ:XCUR)
Historical Stock Chart
From Jul 2023 to Jul 2024